Methodology This prospective follow-up study, conducted from April 2023 to September 2025 at Bangladesh Medical University, enrolled 112 patients (subset of a prior 339-patient cohort) aged >18 years with histologically confirmed cancer and post-treatment cardiotoxicity (defined by elevated troponin-I >0.04 ng/mL, N-terminal pro-brain natriuretic peptide (NT-proBNP) >125 pg/mL, or left ventricular ejection fraction (LVEF) decline ≥10%). Here, NPPB is linked to cancer.